新开发的高纯度人绝经期促性腺激素的临床效用:一项随机对照试验
这项多中心、随机、活性对照、平行设计、开放标签、非劣效性临床研究纳入112例随机接受促性腺激素释放激素拮抗剂方案治疗的不孕女性,其中111例接受治疗。IVF-M HP组与Menopur组获卵数分别为13.1±7.6与10.3±6.7,组间差异的单侧97.5%置信区间下限为-0.25,大于预设非劣效界值-5,故认为IVF-M HP不劣于Menopur。两组在优质卵母细胞数、主导卵泡数、优质胚胎数及受精率、植入率、β-HCG阳性率和临床妊娠率方面均无显著差异;IVF-M HP组与Menopur组分别有40.4%和35.2%报告不良事件。
要点
- IVF-M HP组获卵数13.1±7.6 vs Menopur组10.3±6.7,差异单侧97.5%CI下限-0.25大于非劣效界值-5。
- 两组优质卵母细胞数、主导卵泡数、优质胚胎数及受精率、植入率、β-HCG阳性率、临床妊娠率均无显著差异。
- IVF-M HP组40.4% vs Menopur组35.2%报告不良事件。
核心结论
- IVF-M HP与Menopur具有相当的临床疗效和安全性。
研究设计与样本
- 多中心、随机、活性对照、平行设计、开放标签、非劣效性临床研究。
- 112例接受促性腺激素释放激素拮抗剂方案治疗的不孕女性被随机分组,其中111例接受治疗。
主要发现
- IVF-M HP组与Menopur组获卵数分别为13.1±7.6与10.3±6.7,组间差异的单侧97.5%置信区间下限为-0.25,大于预设非劣效界值-5。
- 两组在优质卵母细胞数、主导卵泡数、优质胚胎数以及受精率、植入率、β-HCG阳性率和临床妊娠率方面均无显著差异。
- IVF-M HP组40.4%与Menopur组35.2%报告不良事件。
关键数值与推荐
- 非劣效界值为-5。
- IVF-M HP组获卵数13.1±7.6 vs Menopur组10.3±6.7,组间差异单侧97.5%置信区间下限-0.25。
- IVF-M HP组不良事件报告率40.4% vs Menopur组35.2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this study was to evaluate the safety and efficacy of IVF-M HP, a newly developed highly purified human menopausal gonadotrophin preparation, for ovarian stimulation in women with infertility undergoing IVF, intracytoplasmic sperm injection (IVF-ICSI) and embryo transfer using a GnRH antagonist protocol. This was a multicentre, randomized, active-controlled, parallel design, open-label, non-inferiority clinical study. Of the 112 patients randomized for treatment using the GnRH antagonist protocol, 111 were treated. No significant difference was found in the number of oocytes retrieved from the IVF-M HP and Menopur groups (13.1 ± 7.6 versus 10.3 ± 6.7, respectively). The lower limit of the one-sided 97.5% confidence interval for the difference between the groups was -0.25, i.e., greater than the pre-defined non-inferiority margin (-5). Therefore, the IVF-M HP treatment was considered non-inferior to Menopur. Furthermore, no significant difference was observed between the groups in the number of good-quality oocytes, leading follicles, good-quality embryos, or in fertilization, implantation, positive beta-HCG and clinical pregnancy rates. The safety analysis revealed that 40.4% and 35.2% in the IVF-M HP and Menopur groups, respectively, reported adverse events. In conclusion, IVF-M HP had comparable clinical efficacy and safety profiles to Menopur.
引用
- Koo HS, Kwon H, Choi DS, et al. Clinical utility of newly developed highly purified human menopausal gonadotrophins: a randomized controlled trial. Reprod Biomed Online. 2017. PMID: 28343757. doi:10.1016/j.rbmo.2017.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。